BDBM107715 US11426393, Compound Table XV.21::US8598210, Table XV, 21::US8722895, 21: {[5-(3-Carbamoyl-phenyl)-3-hydroxy- pyridine-2-carbonyl]-amino}-acetic acid methyl ester::US9598370, Example 00146::USRE47437, Example {[5-(3-Carbamoyl-phenyl)-3-hydroxy-pyridine-2-carbonyl]-amino}-acetic acidmethyl ester

SMILES COC(=O)CNC(=O)c1ncc(cc1O)-c1cccc(c1)C(N)=O

InChI Key InChIKey=MWJDKCNAPFXDPO-UHFFFAOYSA-N

Data  5 IC50  4 EC50

  Tab Delimited (TSV)   2D SDfile   Computed 3D by Vconf -m prep SDfile
Find this compound or compounds like it in BindingDB:
   Substructure
Similarity at least:  must be >=0.5
Exact match

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 9 hits for monomerid = 107715   

TargetEgl nine homolog 1(Homo sapiens (Human))
Akebia Therapeutics

US Patent
LigandPNGBDBM107715(US11426393, Compound Table XV.21 | US8598210, Tabl...)
Affinity DataIC50:  1.12E+4nMAssay Description:The EGLN-1 (or EGLN-3) enzyme activity is determined using mass spectrometry (matrix-assisted laser desorption ionization, time-of-flight MS, MALDI-T...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetVascular endothelial growth factor A(Homo sapiens (Human))
Akebia Therapeutics

US Patent
LigandPNGBDBM107715(US11426393, Compound Table XV.21 | US8598210, Tabl...)
Affinity DataEC50:  5.01E+4nMAssay Description:HEK293 cells are seeded in 96-well poly-lysine coated plates at 20,000 cells per well in DMEM (10% FBS, 1% NEAA, 0.1% glutamine). Following overnight...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetEgl nine homolog 1(Homo sapiens (Human))
Akebia Therapeutics

US Patent
LigandPNGBDBM107715(US11426393, Compound Table XV.21 | US8598210, Tabl...)
Affinity DataIC50:  1.12E+4nMT: 2°CAssay Description:The EGLN-1 (or EGLN-3) enzyme activity is determined using mass spectrometry (matrix-assisted laser desorption ionization, time-of-flight MS, MALDI-T...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetEgl nine homolog 1(Homo sapiens (Human))
Akebia Therapeutics

US Patent
LigandPNGBDBM107715(US11426393, Compound Table XV.21 | US8598210, Tabl...)
Affinity DataIC50:  1.12E+4nMAssay Description:The EGLN-1 (or EGLN-3) enzyme activity is determined using mass spectrometry (matrix-assisted laser desorption ionization, time-of-flight MS, MALDI-T...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetVascular endothelial growth factor receptor 1(Homo sapiens (Human))
Akebia Therapeutics

US Patent
LigandPNGBDBM107715(US11426393, Compound Table XV.21 | US8598210, Tabl...)
Affinity DataEC50:  5.01E+4nMAssay Description:HEK293 cells are seeded in 96-well poly-lysine coated plates at 20,000 ceils per well in DMEM (10% FBS, 1% NEAA, 0.1% glutamine). Following overnight...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetEgl nine homolog 1(Homo sapiens (Human))
Akebia Therapeutics

US Patent
LigandPNGBDBM107715(US11426393, Compound Table XV.21 | US8598210, Tabl...)
Affinity DataIC50:  1.12E+4nMAssay Description:The EGLN-1 (or EGLN-3) enzyme activity is determined using mass spectrometry (matrix-assisted laser desorption ionization, time-of-flight MS, MALDI-T...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetVascular endothelial growth factor A(Homo sapiens (Human))
Akebia Therapeutics

US Patent
LigandPNGBDBM107715(US11426393, Compound Table XV.21 | US8598210, Tabl...)
Affinity DataEC50:  5.01E+4nMAssay Description:HEK293 cells are seeded in 96-well poly-lysine coated plates at 20,000 cells per well in DMEM (10% FBS, 1% NEAA, 0.1% glutamine). Following overnight...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetEgl nine homolog 1 [179-426](Homo sapiens (Human))
Akebia Therapeutics

US Patent
LigandPNGBDBM107715(US11426393, Compound Table XV.21 | US8598210, Tabl...)
Affinity DataIC50:  1.12E+4nMAssay Description:The EGLN-1 (or EGLN-3) enzyme activity is determined using mass spectrometry (matrix-assisted laser desorption ionization, time-of-flight MS, MALDI-T...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetVascular endothelial growth factor A(Homo sapiens (Human))
Akebia Therapeutics

US Patent
LigandPNGBDBM107715(US11426393, Compound Table XV.21 | US8598210, Tabl...)
Affinity DataEC50:  5.01E+4nMMore data for this Ligand-Target Pair
In DepthDetails US Patent